Search Results - "della Porta, M"

Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells by Pellagatti, A, Cazzola, M, Giagounidis, A, Perry, J, Malcovati, L, Della Porta, M G, Jädersten, M, Killick, S, Verma, A, Norbury, C J, Hellström-Lindberg, E, Wainscoat, J S, Boultwood, J

“…To gain insight into the molecular pathogenesis of the myelodysplastic syndromes (MDS), we performed global gene expression profiling and pathway analysis on…”
Get full text

Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia by Boultwood, J, Perry, J, Pellagatti, A, Fernandez-Mercado, M, Fernandez-Santamaria, C, Calasanz, M J, Larrayoz, M J, Garcia-Delgado, M, Giagounidis, A, Malcovati, L, Della Porta, M G, Jädersten, M, Killick, S, Hellström-Lindberg, E, Cazzola, M, Wainscoat, J S

Get full text

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS by Kuendgen, A., Nomdedeu, M., Tuechler, H., Garcia-Manero, G., Komrokji, R. S., Sekeres, M. A., Della Porta, M. G., Cazzola, M., DeZern, A. E., Roboz, G. J., Steensma, D. P., Van de Loosdrecht, A. A., Schlenk, R. F., Grau, J., Calvo, X., Blum, S., Pereira, A., Valent, P., Costa, D., Giagounidis, A., Xicoy, B., Döhner, H., Platzbecker, U., Pedro, C., Lübbert, M., Oiartzabal, I., Díez-Campelo, M., Cedena, M. T., Machherndl-Spandl, S., López-Pavía, M., Baldus, C. D., Martinez-de-Sola, M., Stauder, R., Merchan, B., List, A., Ganster, C., Schroeder, T., Voso, M. T., Pfeilstöcker, M., Sill, H., Hildebrandt, B., Esteve, J., Nomdedeu, B., Cobo, F., Haas, R., Sole, F., Germing, U., Greenberg, P. L., Haase, D., Sanz, G.

“…In the current World Health Organization (WHO)-classification, therapy-related myelodysplastic syndromes (t-MDS) are categorized together with therapy-related…”
Get full text

Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes by Della Porta, M G, Travaglino, E, Boveri, E, Ponzoni, M, Malcovati, L, Papaemmanuil, E, Rigolin, G M, Pascutto, C, Croci, G, Gianelli, U, Milani, R, Ambaglio, I, Elena, C, Ubezio, M, Da Via’, M C, Bono, E, Pietra, D, Quaglia, F, Bastia, R, Ferretti, V, Cuneo, A, Morra, E, Campbell, P J, Orazi, A, Invernizzi, R, Cazzola, M

“…The World Health Organization classification of myelodysplastic syndromes (MDS) is based on morphological evaluation of marrow dysplasia. We performed a…”
Get full text

Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes—proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS by Porwit, A, van de Loosdrecht, A A, Bettelheim, P, Brodersen, L Eidenschink, Burbury, K, Cremers, E, Della Porta, M G, Ireland, R, Johansson, U, Matarraz, S, Ogata, K, Orfao, A, Preijers, F, Psarra, K, Subirá, D, Valent, P, van der Velden, V H J, Wells, D, Westers, T M, Kern, W, Béné, M C

“…Definite progress has been made in the exploration of myelodysplastic syndromes (MDS) by flow cytometry (FCM) since the publication of the World Health…”
Get full text

Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM) by Della Porta, M G, Tuechler, H, Malcovati, L, Schanz, J, Sanz, G, Garcia-Manero, G, Solé, F, Bennett, J M, Bowen, D, Fenaux, P, Dreyfus, F, Kantarjian, H, Kuendgen, A, Levis, A, Cermak, J, Fonatsch, C, Le Beau, M M, Slovak, M L, Krieger, O, Luebbert, M, Maciejewski, J, Magalhaes, S M M, Miyazaki, Y, Pfeilstöcker, M, Sekeres, M A, Sperr, W R, Stauder, R, Tauro, S, Valent, P, Vallespi, T, van de Loosdrecht, A A, Germing, U, Haase, D, Greenberg, P L, Cazzola, M

“…A risk-adapted treatment strategy is mandatory for myelodysplastic syndromes (MDS). We refined the World Health Organization (WHO)-classification-based…”
Get full text

Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome by PORTA, M. G. Della, MALCOVATI, L, MARSEGLIA, C, LEVI, S, AROSIO, P, LAZZARINO, M, CAZZOLA, M, INVERNIZZI, R, TRAVAGLINO, E, PASCUTTO, C, MAFFIOLI, M, GALLI, A, BOGGI, S, PIETRA, D, VANELLI, L

“…Erythroid dysplasia is the pathologic hallmark of myelodysplastic syndromes (MDS). To develop a quantitative flow-cytometry approach to its evaluation, we…”
Get full text

Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group by Westers, T M, Ireland, R, Kern, W, Alhan, C, Balleisen, J S, Bettelheim, P, Burbury, K, Cullen, M, Cutler, J A, Della Porta, M G, Dräger, A M, Feuillard, J, Font, P, Germing, U, Haase, D, Johansson, U, Kordasti, S, Loken, M R, Malcovati, L, te Marvelde, J G, Matarraz, S, Milne, T, Moshaver, B, Mufti, G J, Ogata, K, Orfao, A, Porwit, A, Psarra, K, Richards, S J, Subirá, D, Tindell, V, Vallespi, T, Valent, P, van der Velden, V H J, de Witte, T M, Wells, D A, Zettl, F, Béné, M C, van de Loosdrecht, A A

“…Flow cytometry (FC) is increasingly recognized as an important tool in the diagnosis and prognosis of myelodysplastic syndromes (MDS). However, validation of…”
Get full text

Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome by MALCOVATI, L, PORTA, M. G, CAZZOLA, M, LUNGHI, M, PASCUTTO, C, VANELLI, L, TRAVAGLINO, E, MAFFIOLI, M, BERNASCONI, P, LAZZARINO, M, INVERNIZZI, R

“…The purpose of this study was to develop a flow cytometric approach to the evaluation of marrow dysplasia in myelodysplastic syndromes (MDS). We first studied…”
Get full text

Chronic lymphocytic leukemia with 6q− shows distinct hematological features and intermediate prognosis by CUNEO, A, RIGOLIN, G. M, CICCONE, M, DELLA PORTA, M, TIEGHI, A, CAVAZZINI, L, NEGRINI, M, CASTOLDI, G, BIGONI, R, DE ANGELI, C, VERONESE, A, CAVAZZINI, F, BARDI, A, ROBERTI, M. G, TAMMISO, E, AGOSTINI, P

“…Cytogenetic and fluorescence in situ hybridization studies were successfully performed in 217 chronic lymphocytic leukemia (CLL). In all, 13 patients with 6q21…”
Get full text

Immunophenotypic, cytogenetic and functional characterization of circulating endothelial cells in myelodysplastic syndromes by Della Porta, M G, Malcovati, L, Rigolin, G M, Rosti, V, Bonetti, E, Travaglino, E, Boveri, E, Gallì, A, Boggi, S, Ciccone, M, Pramparo, T, Mazzini, G, Invernizzi, R, Lazzarino, M, Cazzola, M

“…Circulating endothelial cells (CECs) are associated with neoangiogenesis in various malignant disorders. Using flow cytometry, we studied CECs in 128 patients…”
Get full text

Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study by DELLA PORTA, Matteo G, PICONE, Cristina, SAFT, Leonie, WESTERS, Theresia M, ALHAN, Canan, CALI, Claudia, DE LOOSDRECHT, Arjan A. Van, OGATA, Kiyoyuki, PASCUTTO, Cristiana, MALCOVATI, Luca, TAMURA, Hideto, HANDA, Hiroshi, CZADER, Magdalena, FREEMAN, Sylvie, VYAS, Paresh, PORWIT, Anna

“…The current World Health Organization classification of myelodysplastic syndromes is based morphological evaluation of bone marrow dysplasia. In clinical…”
Get full text

Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype by RIGOLIN, G. M, BIGONI, R, CUNEO, A, CASTOLDI, G, MILANI, R, CAVAZZINI, F, ROBERTI, M. G, BARDI, A, AGOSTINI, P, DELLA PORTA, M, TIEGHI, A, PIVA, N

“…At diagnosis, approximately half of myelodysplastic (MDS) patients presents a normal karyotype by conventional cytogenetic analysis (CCA). Fluorescent in situ…”
Get full text

Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System by Della Porta, M G, Jackson, C H, Alessandrino, E P, Rossi, M, Bacigalupo, A, van Lint, M T, Bernardi, M, Allione, B, Bosi, A, Guidi, S, Santini, V, Malcovati, L, Ubezio, M, Milanesi, C, Todisco, E, Voso, M T, Musto, P, Onida, F, Iori, A P, Cerretti, R, Grillo, G, Molteni, A, Pioltelli, P, Borin, L, Angelucci, E, Oldani, E, Sica, S, Pascutto, C, Ferretti, V, Santoro, A, Bonifazi, F, Cazzola, M, Rambaldi, A

“…Allogeneic hematopoietic stem cell transplantation (allo-SCT) represents the only curative treatment for patients with myelodysplastic syndrome (MDS), but…”
Get full text

A continuous-time Markov model approach for modeling myelodysplastic syndromes progression from cross-sectional data by Nicora, G., Moretti, F., Sauta, E., Della Porta, M., Malcovati, L., Cazzola, M., Quaglini, S., Bellazzi, R.

“…[Display omitted] •Simulation of longitudinal data from cross-sectional based on patient similarity.•Simulation describes disease progression with trajectories…”
Get full text

Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDS flow working group by Kern, Wolfgang, Westers, Theresia M., Bellos, Frauke, Bene, Marie Christine, Bettelheim, Peter, Brodersen, Lisa Eidenschink, Burbury, Kate, Chu, Sung‐Chao, Cullen, Matthew, Porta, Matteo Della, Dunlop, Alan Stewart, Johansson, Ulrika, Matarraz, Sergio, Oelschlaegel, Uta, Ogata, Kiyoyuki, Porwit, Anna, Preijers, Frank, Psarra, Katherina, Saft, Leonie, Subirá, Dolores, Weiß, Elisabeth, Velden, Vincent H. J., Loosdrecht, Arjan

“…Background Myelodysplastic syndromes (MDS) represent a diagnostic challenge. This prospective multicenter study was conducted to evaluate pre‐defined flow…”
Get full text

PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia by Passamonti, F, Pietra, D, Rumi, E, Arcaini, L, Della Porta, M G, Malcovati, L, Pascutto, C, Lazzarino, M, Cazzola, M

Get full text

EFFICACY AND SAFETY OF LUSPATERCEPT VERSUS EPOETIN ALFA IN ERYTHROPOIESIS-STIMULATING AGENT (ESA)-NAIVE PATIENTS WITH TRANSFUSION-DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FULL ANALYSIS OF THE COMMANDS TRIAL by Garcia-Manero, G., Platzbecker, U., Santini, V., Zeidan, A., Fenaux, P., Komrokji, R., Shortt, J., Valcarcel, D., Jonasova, A., Dimicoli-Salazar, S., Tiong, I.S., Lin, C.-C., Li, J., Zhang, J., Giuseppi, A.C., Kreitz, S., Pozharskaya, V., Keeperman, K., Rose, S., Prebet, T., Degulys, A., Paolini, S., Cluzeau, T., Porta, M. Della

“…We report the full analysis of the COMMANDS trial assessing efficacy and safety of luspatercept versus epoetin alfa (EA) in ESA-naive patients with LR-MDS. 363…”
Get full text

SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts by Malcovati, Luca, Karimi, Mohsen, Papaemmanuil, Elli, Ambaglio, Ilaria, Jädersten, Martin, Jansson, Monika, Elena, Chiara, Gallì, Anna, Walldin, Gunilla, Della Porta, Matteo G., Raaschou-Jensen, Klas, Travaglino, Erica, Kallenbach, Klaus, Pietra, Daniela, Ljungström, Viktor, Conte, Simona, Boveri, Emanuela, Invernizzi, Rosangela, Rosenquist, Richard, Campbell, Peter J., Cazzola, Mario, Hellström Lindberg, Eva

“…Refractory anemia with ring sideroblasts (RARS) is a myelodysplastic syndrome (MDS) characterized by isolated erythroid dysplasia and 15% or more bone marrow…”
Get full text

Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes by Gerstung, Moritz, Pellagatti, Andrea, Malcovati, Luca, Giagounidis, Aristoteles, Porta, Matteo G Della, Jädersten, Martin, Dolatshad, Hamid, Verma, Amit, Cross, Nicholas C. P., Vyas, Paresh, Killick, Sally, Hellström-Lindberg, Eva, Cazzola, Mario, Papaemmanuil, Elli, Campbell, Peter J., Boultwood, Jacqueline

“…Cancer is a genetic disease, but two patients rarely have identical genotypes. Similarly, patients differ in their clinicopathological parameters, but how…”
Get full text